Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Questions Raised Regarding NHI Prices of Interferons
December 10, 2001
- Ohki: Sales Up 2.7%, Operating Profits Up 22.0%
December 10, 2001
- Sales of 4 New Drugs Including Advaferon, Palmicort Expected to Exceed \10 Bil.
December 10, 2001
- DIAGNOSTIC NEWS IN BRIEF
December 10, 2001
- 9 NCEs Including Glivec, Rebetol Listed
December 10, 2001
- MEDICAL DEVICE NEWS IN BRIEF
December 10, 2001
- Korosho to Regard Original Products without Generics as Long-listed
December 10, 2001
- Shimadzu: New Electronic Medical Chart System
December 10, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
December 10, 2001
- WORLD NEWS IN BRIEF
December 10, 2001
- Vital-Net: Operating Profits Drop Despite Big Increases in Sales
December 10, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
December 10, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -2-
December 10, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -1-
December 10, 2001
- Drug Firms Increasing Investment in R&D
December 10, 2001
- Sales of 30 Major Makers Up 2.3%, Profits Up 55.9%
December 10, 2001
- PhRMA Calls For Abolition of Re-pricing System
December 10, 2001
- BUSINESS NEWS IN BRIEF
December 10, 2001
- Inabata to Gear Up Drug, Health Food Business
December 10, 2001
- Chugai Withdraws from Medical Devices to Concentrate on Drug Business
December 10, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…